SOUTH SAN FRANCISCO & LOS ANGELES & SAN DIEGO & WASHINGTON–(BUSINESS WIRE)–Biocom California, the association representing the California life sciences industry, has issued the following statement regarding the adoption of fiscal year (FY) 2023 continuous resolution in the Senate and the House of Representatives this week. The statement can be attributed to Joe Panetta, President and CEO of Biocom California:
“Biocom California applauds the Senate and House of Representatives for passing legislation that not only funds federal agencies at fiscal year 2022 levels through December 16, but also reauthorizes Food User Fee Agreements. and Drug Administration (FDA) through fiscal year 2027. The measure avoids both a government shutdown and an expiration of the FDA’s authority to collect and spend user fees, which would have had dire consequences for the life sciences industry.
“California is a global leader in biomedical innovation, generating more than $400 billion in annual economic activity and supporting more than 1.4 million jobs. The bill is critical to ensuring that the FDA is well funded and can continue to review and approve products vital to the more than 12,000 life science institutions that call California home. These agreements are negotiated by the FDA and the life sciences industry every five years and have helped reduce application backlogs, hire specialized staff, approve breakthrough technologies and better engage patients.
“Biocom California also commends House and Senate committee staff who worked tirelessly this year to include important provisions, such as increasing diversity in clinical trials and improving the workforce. work of the FDA, which were not included in the final measure. We look forward to working with Congress to address these important priorities in future legislation.
“We also urge both chambers to meet in December to pass a full-year omnibus to provide much-needed funding increases to federal agencies and their underlying programs that are at the forefront of advancing the 21st century medicine and giving hope to patients around the world, including the FDA, the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Biomedical Advanced Research and Development Authority (BARDA ).
About Biocom California
Biocom California is the leader and advocate for the life sciences industry in California. We work on behalf of over 1,700 members to drive public policybuild an enviable network of industry leaderscreate access to capitalintroduce cutting-edge STEM education programs and create strong values purchasing programs.
Founded in 1995 in San Diego, Biocom California provides the loudest public voice for research institutions and businesses that fuel the local and statewide economy. Our goal is simple: to help our members produce innovative solutions that improve the human condition. In addition to our San Diego HeadquartersBiocom California operates central offices in Los Angeles and the San Francisco Bay Areawith satellite offices in Sacramento, washington d.c. and Tokyo. Our many membership benefits apply to biotechnology, pharmaceutical, medical device, genomics and diagnostics companies of all sizes, as well as universities and research institutes, clinical research organizations, investors and suppliers. Services.